Bayer’s High-Stakes Summer: A $7.25 Billion Settlement and a Pivotal Supreme Court Hearing

Bayer is entering a defining period for its legal and financial future. The German life sciences group has secured preliminary court approval for a settlement worth up to $7.25 billion to resolve thousands of Roundup lawsuits, while simultaneously awaiting a US Supreme Court ruling that could fundamentally alter its legal landscape. The convergence of these events has left the stock trading near multi-month lows, with investors weighing the cost of closure against the prospect of a structural breakthrough.

The Settlement Clock Is Ticking

On March 4, 2026, a federal judge in St. Louis gave provisional approval to a sweeping settlement covering claims linking the herbicide Roundup to non-Hodgkin lymphoma. The deal, which Bayer will fund over a maximum of 21 years, is not yet final. Claimants have until June 4, 2026, to opt out or file objections, and the court will hold a fairness hearing on July 9, 2026, before granting final approval.

The financial burden on Bayer has been severe. In fiscal 2025, special charges for litigation ballooned to €6.2 billion, dragging the group’s net result to a loss of €3.6 billion. The company has warned that free cash flow will remain negative in 2026, largely due to expected cash outflows of around €5 billion for ongoing legal proceedings.

Supreme Court Showdown Could Rewrite the Rules

Running parallel to the settlement process is a case that could render much of Bayer’s glyphosate litigation moot. On April 27, 2026, the US Supreme Court will hear oral arguments in the so-called Durnell case. At its core is a preemption question: can federal law override state-level labeling requirements for glyphosate-based products? A ruling in Bayer’s favor, expected in June 2026, would potentially invalidate thousands of remaining claims.

The stakes could not be higher. A favorable Supreme Court decision would represent a structural victory, removing the legal overhang that has weighed on the stock for years. Analysts at JPMorgan, who maintain an “Overweight” rating with a €50 fair value target, see this as a potential catalyst. Goldman Sachs has also expressed optimism about Bayer’s pharma pipeline, particularly the menopause drug Lynkuet.

Should investors sell immediately? Or is it worth buying Bayer?

Shareholders Get the Minimum

Against this backdrop, Bayer’s annual general meeting delivered a clear message: debt reduction comes first. The company will pay a dividend of just €0.11 per share for fiscal 2025, the legal minimum, with payment scheduled for April 29, 2026. This policy is locked in for three years as management prioritizes lowering net financial debt and funneling cash into the pharma pipeline.

CEO Bill Anderson defended the strategy, arguing that the freed-up resources will support the company’s “Dynamic Shared Ownership” restructuring model, which aims to flatten hierarchies and accelerate decision-making. The transformation, he acknowledged, is not yet complete. The AGM also elected two new supervisory board members: Marcel Smits, former CFO of Cargill, and Alfred Stern, CEO of energy group OMV, bringing fresh expertise in strategy and industrial operations.

Stock Under Pressure

The market’s reaction has been unforgiving. Bayer shares closed at €38.50 on Friday, down 3.85% on the day and roughly 22% below the 52-week high of €49.17 reached in February. The stock now trades below both its 50-day moving average and its 200-day moving average, with a relative strength index of 46.8, indicating neutral but fragile momentum.

The next major catalyst comes on May 12, 2026, when Bayer releases its first-quarter results. For the full year, management has guided for adjusted earnings per share of between €4.30 and €4.80, a wide range that reflects the uncertainty surrounding the Supreme Court outcome. That compares with an unadjusted loss per share of €3.68 in 2025.

For now, Bayer’s fate hangs on two legal processes running on separate tracks: a settlement that offers a costly but controlled resolution, and a Supreme Court decision that could deliver a sweeping victory. The next few months will determine which path the company ultimately takes.